Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zecevic

Showing results (261-270 of 278) with videos related to

Pageof 28
Sort By:
Radiology|January 19, 2021
Virtual Unenhanced Dual-Energy CT Images Obtained with a Multimaterial Decomposition Algorithm: Diagnostic Value for Renal Mass and Urinary Stone EvaluationJennifer M Xiao, Daniel S Hippe, Mladen Zecevic, et al.
European Journal of Clinical Pharmacology|October 25, 2012
Population pharmacokinetics of bisoprolol in patients with chronic heart failureValentina N Nikolic, Tatjana Jevtovic-Stoimenov, Radmila Velickovic-Radovanović, et al.
Plos One|December 31, 2020
SARS-CoV-2 infection induces mixed M1/M2 phenotype in circulating monocytes and alterations in both dendritic cell and monocyte subsetsSanja Matic, Suzana Popovic, Predrag Djurdjevic, et al.
Canadian Geriatrics Journal : CGJ|October 24, 2015
Mobility and Cognition in Seniors. Report from the 2008 Institute of Aging (CIHR) Mobility and Cognition WorkshopManuel Montero-Odasso, Louis Bherer, Stephanie Studenski, et al.
Neurology|April 17, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II StudyScott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Annals of Clinical and Translational Neurology|October 26, 2024
Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I studyScott D Newsome, Lawrence Goldstick, Derrick S Robertson, et al.
Nature Neuroscience|September 15, 2009
AP2gamma regulates basal progenitor fate in a region- and layer-specific manner in the developing cortexLuisa Pinto, Daniela Drechsel, Marie-Theres Schmid, et al.
Zeitschrift Fur Gerontologie Und Geriatrie|November 26, 2013
Development of a standard fall data format for signals from body-worn sensors : the FARSEEING consensusJ Klenk, L Chiari, J L Helbostad, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Safety Profile of Antipsychotics as Predictors of the Quality of Life in Patients with Schizophrenia-An Inpatient Welfare Institution-Based Cross-Sectional StudyAleksandra D Petrovic, Ana M Barjaktarevic, Olivera Z Kostic, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trialsStephen L Hauser, Gavin Giovannoni, Xavier Montalban, et al.
Pageof 28

Showing results (261-270 of 278) with videos related to

Sort By:
Pageof 28
Radiology|January 19, 2021
Virtual Unenhanced Dual-Energy CT Images Obtained with a Multimaterial Decomposition Algorithm: Diagnostic Value for Renal Mass and Urinary Stone EvaluationJennifer M Xiao, Daniel S Hippe, Mladen Zecevic, et al.
European Journal of Clinical Pharmacology|October 25, 2012
Population pharmacokinetics of bisoprolol in patients with chronic heart failureValentina N Nikolic, Tatjana Jevtovic-Stoimenov, Radmila Velickovic-Radovanović, et al.
Plos One|December 31, 2020
SARS-CoV-2 infection induces mixed M1/M2 phenotype in circulating monocytes and alterations in both dendritic cell and monocyte subsetsSanja Matic, Suzana Popovic, Predrag Djurdjevic, et al.
Canadian Geriatrics Journal : CGJ|October 24, 2015
Mobility and Cognition in Seniors. Report from the 2008 Institute of Aging (CIHR) Mobility and Cognition WorkshopManuel Montero-Odasso, Louis Bherer, Stephanie Studenski, et al.
Neurology|April 17, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II StudyScott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Annals of Clinical and Translational Neurology|October 26, 2024
Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I studyScott D Newsome, Lawrence Goldstick, Derrick S Robertson, et al.
Nature Neuroscience|September 15, 2009
AP2gamma regulates basal progenitor fate in a region- and layer-specific manner in the developing cortexLuisa Pinto, Daniela Drechsel, Marie-Theres Schmid, et al.
Zeitschrift Fur Gerontologie Und Geriatrie|November 26, 2013
Development of a standard fall data format for signals from body-worn sensors : the FARSEEING consensusJ Klenk, L Chiari, J L Helbostad, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Safety Profile of Antipsychotics as Predictors of the Quality of Life in Patients with Schizophrenia-An Inpatient Welfare Institution-Based Cross-Sectional StudyAleksandra D Petrovic, Ana M Barjaktarevic, Olivera Z Kostic, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trialsStephen L Hauser, Gavin Giovannoni, Xavier Montalban, et al.
Pageof 28